173 related articles for article (PubMed ID: 37968472)
1. APC/PIK3CA mutations and β-catenin status predict tankyrase inhibitor sensitivity of patient-derived colorectal cancer cells.
Chen M; Mashima T; Oishi T; Muramatsu Y; Seto Y; Takamatsu M; Kawata N; Morino S; Nakamura A; Inaba S; Yuan X; Maruyama K; Suzuki M; Sato A; Yoshida H; Jang MK; Mizutani A; Takeuchi K; Yamaguchi K; Shirai F; Nagayama S; Katayama R; Seimiya H
Br J Cancer; 2024 Jan; 130(1):151-162. PubMed ID: 37968472
[TBL] [Abstract][Full Text] [Related]
2.
Tanaka N; Mashima T; Mizutani A; Sato A; Aoyama A; Gong B; Yoshida H; Muramatsu Y; Nakata K; Matsuura M; Katayama R; Nagayama S; Fujita N; Sugimoto Y; Seimiya H
Mol Cancer Ther; 2017 Apr; 16(4):752-762. PubMed ID: 28179481
[TBL] [Abstract][Full Text] [Related]
3. A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.
Lau T; Chan E; Callow M; Waaler J; Boggs J; Blake RA; Magnuson S; Sambrone A; Schutten M; Firestein R; Machon O; Korinek V; Choo E; Diaz D; Merchant M; Polakis P; Holsworth DD; Krauss S; Costa M
Cancer Res; 2013 May; 73(10):3132-44. PubMed ID: 23539443
[TBL] [Abstract][Full Text] [Related]
4. RK-287107, a potent and specific tankyrase inhibitor, blocks colorectal cancer cell growth in a preclinical model.
Mizutani A; Yashiroda Y; Muramatsu Y; Yoshida H; Chikada T; Tsumura T; Okue M; Shirai F; Fukami T; Yoshida M; Seimiya H
Cancer Sci; 2018 Dec; 109(12):4003-4014. PubMed ID: 30238564
[TBL] [Abstract][Full Text] [Related]
5. Tankyrase-selective inhibitor STP1002 shows preclinical antitumour efficacy without on-target toxicity in the gastrointestinal tract.
Kim DY; Kwon YJ; Seo WY; Kim UI; Ahn S; Choi SM; Bang HT; Kim K; Kim JS
Eur J Cancer; 2022 Sep; 173():41-51. PubMed ID: 35849876
[TBL] [Abstract][Full Text] [Related]
6. Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer.
Arqués O; Chicote I; Puig I; Tenbaum SP; Argilés G; Dienstmann R; Fernández N; Caratù G; Matito J; Silberschmidt D; Rodon J; Landolfi S; Prat A; Espín E; Charco R; Nuciforo P; Vivancos A; Shao W; Tabernero J; Palmer HG
Clin Cancer Res; 2016 Feb; 22(3):644-56. PubMed ID: 26224873
[TBL] [Abstract][Full Text] [Related]
7. mTOR signaling mediates resistance to tankyrase inhibitors in Wnt-driven colorectal cancer.
Mashima T; Taneda Y; Jang MK; Mizutani A; Muramatsu Y; Yoshida H; Sato A; Tanaka N; Sugimoto Y; Seimiya H
Oncotarget; 2017 Jul; 8(29):47902-47915. PubMed ID: 28615517
[TBL] [Abstract][Full Text] [Related]
8. BET protein-dependent E2F pathway activity confers bell-shaped type resistance to tankyrase inhibitors in APC-mutated colorectal cancer.
Morino S; Mashima T; Shirai F; Nagayama S; Katayama R; Seimiya H
Cancer Lett; 2024 Mar; 584():216632. PubMed ID: 38216082
[TBL] [Abstract][Full Text] [Related]
9. APC truncating mutations in Middle Eastern Population: Tankyrase inhibitor is an effective strategy to sensitize APC mutant CRC To 5-FU chemotherapy.
Siraj AK; Kumar Parvathareddy S; Pratheeshkumar P; Padmaja Divya S; Ahmed SO; Melosantos R; Begum R; Concepcion RMJA; Al-Sanea N; Ashari LH; Abduljabbar A; Al-Dayel F; Al-Kuraya KS
Biomed Pharmacother; 2020 Jan; 121():109572. PubMed ID: 31704613
[TBL] [Abstract][Full Text] [Related]
10. Activation of WNT/β-catenin signaling results in resistance to a dual PI3K/mTOR inhibitor in colorectal cancer cells harboring PIK3CA mutations.
Park YL; Kim HP; Cho YW; Min DW; Cheon SK; Lim YJ; Song SH; Kim SJ; Han SW; Park KJ; Kim TY
Int J Cancer; 2019 Jan; 144(2):389-401. PubMed ID: 29978469
[TBL] [Abstract][Full Text] [Related]
11. TRIB3 Interacts With β-Catenin and TCF4 to Increase Stem Cell Features of Colorectal Cancer Stem Cells and Tumorigenesis.
Hua F; Shang S; Yang YW; Zhang HZ; Xu TL; Yu JJ; Zhou DD; Cui B; Li K; Lv XX; Zhang XW; Liu SS; Yu JM; Wang F; Zhang C; Huang B; Hu ZW
Gastroenterology; 2019 Feb; 156(3):708-721.e15. PubMed ID: 30365932
[TBL] [Abstract][Full Text] [Related]
12. Tankyrase inhibitors attenuate WNT/β-catenin signaling and inhibit growth of hepatocellular carcinoma cells.
Ma L; Wang X; Jia T; Wei W; Chua MS; So S
Oncotarget; 2015 Sep; 6(28):25390-401. PubMed ID: 26246473
[TBL] [Abstract][Full Text] [Related]
13. Tankyrase Inhibitors Target Colorectal Cancer Stem Cells via AXIN-Dependent Downregulation of c-KIT Tyrosine Kinase.
Jang MK; Mashima T; Seimiya H
Mol Cancer Ther; 2020 Mar; 19(3):765-776. PubMed ID: 31907221
[TBL] [Abstract][Full Text] [Related]
14. TANKYRASE Inhibition Enhances the Antiproliferative Effect of PI3K and EGFR Inhibition, Mutually Affecting β-CATENIN and AKT Signaling in Colorectal Cancer.
Solberg NT; Waaler J; Lund K; Mygland L; Olsen PA; Krauss S
Mol Cancer Res; 2018 Mar; 16(3):543-553. PubMed ID: 29222171
[TBL] [Abstract][Full Text] [Related]
15. Interaction of tankyrase and peroxiredoxin II is indispensable for the survival of colorectal cancer cells.
Kang DH; Lee DJ; Lee S; Lee SY; Jun Y; Kim Y; Kim Y; Lee JS; Lee DK; Lee S; Jho EH; Yu DY; Kang SW
Nat Commun; 2017 Jun; 8(1):40. PubMed ID: 28659575
[TBL] [Abstract][Full Text] [Related]
16. A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.
Waaler J; Machon O; Tumova L; Dinh H; Korinek V; Wilson SR; Paulsen JE; Pedersen NM; Eide TJ; Machonova O; Gradl D; Voronkov A; von Kries JP; Krauss S
Cancer Res; 2012 Jun; 72(11):2822-32. PubMed ID: 22440753
[TBL] [Abstract][Full Text] [Related]
17. Structure, Dynamics, and Functionality of Tankyrase Inhibitor-Induced Degradasomes.
Thorvaldsen TE; Pedersen NM; Wenzel EM; Schultz SW; Brech A; Liestøl K; Waaler J; Krauss S; Stenmark H
Mol Cancer Res; 2015 Nov; 13(11):1487-501. PubMed ID: 26124443
[TBL] [Abstract][Full Text] [Related]
18. The Discovery and Characterization of K-756, a Novel Wnt/β-Catenin Pathway Inhibitor Targeting Tankyrase.
Okada-Iwasaki R; Takahashi Y; Watanabe Y; Ishida H; Saito J; Nakai R; Asai A
Mol Cancer Ther; 2016 Jul; 15(7):1525-34. PubMed ID: 27196752
[TBL] [Abstract][Full Text] [Related]
19. Regulation of Wnt/β-catenin signalling by tankyrase-dependent poly(ADP-ribosyl)ation and scaffolding.
Mariotti L; Pollock K; Guettler S
Br J Pharmacol; 2017 Dec; 174(24):4611-4636. PubMed ID: 28910490
[TBL] [Abstract][Full Text] [Related]
20. Stabilizing and upregulating Axin with tankyrase inhibitor reverses 5-fluorouracil chemoresistance and proliferation by targeting the WNT/caveolin-1 axis in colorectal cancer cells.
Luo F; Li J; Liu J; Liu K
Cancer Gene Ther; 2022 Nov; 29(11):1707-1719. PubMed ID: 35750753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
